Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
New Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.